Company / Gross Profit
United Therapeutics Gross Profit History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$2.8B
FY2025
5-year range
$1.6B / $2.8B
FY2021-FY2025
Trend
+9.0%
vs FY2024
Sector context
#6 of 29
Health Care
What the data says
United Therapeutics's gross profit of $2.8B is higher than 79% of companies in the Health Care sector (FY2025). Gross Profit has increased for 7 consecutive years, from $336M in FY2018 to $2.8B in FY2025.
Based on SEC 10-K filings.
$2.8B in FY2025 with a 5-year CAGR of +15.3%. Top quartile in the Health Care sector.
Improved from $2.1B to $2.8B over the past 2 years.
Health Care sector context is included.
Gross Profit over time
Growth rates
- 3-Year CAGR
- +16.2%
- 5-Year CAGR
- +15.3%
- 10-Year CAGR
- -
Sector benchmark
Top 21% in Health CareTop 21% of 29This company $2.8B Sector average $3.5B
▼
-19.2% below sector average
Key checks
Key Insights
- United Therapeutics's gross profit has grown for 7 consecutive years.
- 5-year CAGR of +15.3%, indicating consistent growth.
- In FY2025, gross profit increased 9.0% year-over-year.
- Ranks #6 out of 29 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 6.00 (safe zone, above 2.9 threshold)
- Strong profit margin: 40.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.8B | +9.0% |
| FY2024 | $2.6B | +24.0% |
| FY2023 | $2.1B | +16.0% |
| FY2022 | $1.8B | +14.2% |
| FY2021 | $1.6B | +13.7% |
| FY2020 | $1.4B | +3.3% |
| FY2019 | $1.3B | +296.2% |
| FY2018 | $336.0M | -5.7% |
| FY2017 | $356.2M | -3.3% |
| FY2016 | $368.3M | +20.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026